uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

Go back to uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
CARLISLE COMPANIES, Inc. (NYSE: CSL) Delayed: 320.36 --0 (-0%)
Previous Close $320.36    52 Week High $114.49 
Open $320.36    52 Week Low $75.17 
Day High $320.36    P/E 88.74 
Day Low $320.36    EPS $3.61 
Volume 36       

(AMEX: CSLLY) Delayed: 32.21 --0 (-0%)
Previous Close $32.21    52 Week High $45.60 
Open $32.21    52 Week Low $33.39 
Day High $32.21    P/E N/A 
Day Low $32.21    EPS $0.00 
Volume 809       

UNIQURE (NASDAQ: QURE) Delayed: 22.59 --0 (-0%)
Previous Close $22.59    52 Week High $22.79 
Open $22.59    52 Week Low $6.63 
Day High $22.59    P/E N/A 
Day Low $22.59    EPS $0.00 
Volume 1,616